Cost-Effectiveness Of Idelalisib In Combination With Rituximab For The Treatment Of Relapsed/Refractory Chronic Lymphocytic Leukemia (Cll) In Portugal
AuthID
P-00P-C6Y
P-00P-C6Y
© 2024 CRACS & Inesc TEC - All Rights Reserved Política de Privacidade | Terms of Service